REVELATION BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The following documents are filed as part of this Annual Report:
| EXHIBIT | DESCRIPTION |
| 3.1(1) | Third Amended and Restated Certificate of Incorporation |
| 3.2(2) | Amendment to the Third Amended and Restated Certificate of Incorporation, effective February 1, 2023 |
| 3.3(3) | Amendment to the Third Amended and Restated Certificate of Incorporation, effective January 22, 2024 |
| 3.4(4) | Amendment to the Third Amended and Restated Certificate of Incorporation, effective July 7, 2025 |
| 3.5(5) | Amended and Restated Bylaws |
| 4.1(1) | Specimen Common Stock Certificate |
| 4.2(1) | Specimen Warrant Certificate for Public Warrants |
| 4.3(1) | Warrant Agreement, dated October 7, 2020, between Continental Stock Transfer & Trust Company and the Company |
| 4.4(6) | Form of Unregistered Class A Common Stock Purchase Warrant dated January 25, 2022 |
| 4.5(6) | Form of Unregistered Class A Placement Agent Warrant dated January 25, 2022 |
| 4.6(7) | Form of Class B Common Stock Warrant dated July 28, 2022 |
| 4.7(7) | Form of Class B Placement Agent Common Stock Purchase Warrant dated July 28, 2022 |
| 4.8(7) | Warrant Agency Agreement with Continental Stock Transfer & Trust Co. dated July 28, 2022 |
| 4.9(8) | Form of Class C Common Stock Warrant dated February 13, 2023 |
| 4.10(8) | Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. dated February 13, 2023 |
| 4.11(9) | Form of Class D Common Stock Warrant dated February 5, 2024 |
| 4.12(9) | Form of Warrant Agency Agreement with Continental Stock Transfer & Trust Co. dated February 5, 2024 |
| 4.13(10) | Form of Warrant Agency Agreement with Continental Stock Transfer & Co., dated May 29, 2025 |
| 4.14(11) | Form of Class E Common Stock Warrant dated August 22, 2024 |
| 4.15(12) | Form of Class G Common Stock Warrant dated December 3, 2024 |
| 4.16(10) | Form of Class H Common Stock Warrant, dated May 29, 2025 |
| 4.17(13) | Form of Class I Common Stock Warrant, dated September 11, 2025 |
| 4.18* | Form of Class J Common Stock Warrant, dated January 23, 2026 |
| 4.19* | Description of Securities |
| 10.1†(14) | Revelation Biosciences, Inc. 2021 Equity Incentive Plan, as amended |
| 10.2†(1) | Executive Employment Agreement between Revelation Biosciences, Inc. and James Rolke, effective July 27, 2021 |
| 10.3†(1) | Executive Employment Agreement between Revelation Biosciences, Inc. and Chester S. Zygmont, III, effective July 27, 2021 |
| 10.4(1) | Revelation Common Stock Warrant Issued to National Securities Corporation |
| 10.5(6) | Securities Purchase Agreement dated January 23, 2022 by and between the Company and Armistice Capital Master Fund Ltd. |
| 10.6(8) | Form of Securities Purchase Agreement dated February 9, 2023 |
| 10.7(9) | Form of Securities Purchase Agreement dated February 1, 2024 |
| 10.8(10) | Form of Securities Purchase Agreement, dated May 28, 2025 |
| 10.9(8) | Form of Placement Agency Agreement dated February 9, 2023 |
| 10.10(9) | Form of Placement Agency Agreement dated February 1, 2024 |
| 10.11(10) | Form of Placement Agency Agreement, dated May 28, 2025 |
| 10.12* | Form of Inducement Letter, dated January 23, 2026 |
| 14.1(15) | Code of Ethics |
| 19.1(16) | Insider Trader Policy |
| 21.1(17) | List of Subsidiaries. |
| 23.1* | Consent of Baker Tilly US, LLP, independent registered public accounting firm of Revelation Biosciences, Inc. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 97(18) | Claw Back Policy |
| 99.1(15) | Audit Committee Charter |
| 99.2(15) | Compensation Committee Charter |
| 99.3(15) | Nominating Committee Charter |
| 101.INS* | XBRL Instance Document – the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
The annexes, schedules, and certain exhibits to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Revelation hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.
| (1) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form S-4 filed, as amended (File No. 333- 259638). |
| (2) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on January 31, 2023. |
| (3) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on January 23, 2024. |
| (4) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on July 9, 2025. |
| (5) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on July 7, 2023. |
| (6) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on January 27, 2022. |
| (7) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Registration Statement on Form S-1, as amended (File No. 333-268076). |
| (8) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on February 13, 2023. |
| (9) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on February 8, 2024. |
| (10) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on June 4, 2025. |
| (11) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on August 26, 2024. |
| (12) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on December 6, 2024. |
| (13) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on September 15, 2025 |
| (14) | Previously filed Appendix A to Revelation Biosciences, Inc.’s definitive proxy statement filed on June 6, 2025. |
| (15) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Annual Report on Form 10-K filed on March 30, 2023. |
| (16) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Annual Report on Form 10-K filed on March 6, 2025. |
| (17) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Current Report on Form 8-K filed on January 14, 2022. |
| (18) | Previously filed as an exhibit to Revelation Biosciences, Inc.’s Annual Report on Form 10-K filed on March 22, 2024. |
| * | Filed herewith. |
| † | Indicates a management contract or compensatory plan. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.